GT Biopharma, Inc. - FORM 10-Q - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - August 11, 2017

Attached files

file filename
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.oxis_ex311.htm
10-Q - QUARTERLY REPORT - GT Biopharma, Inc.oxis_10q.htm
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - GT Biopharma, Inc.oxis_ex322.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.oxis_ex312.htm
EX-10.4 - LICENSE AGREEMENT WITH DANIEL A. VALLERA, PH.D. - GT Biopharma, Inc.oxis_ex104.htm
EX-10.3 - LICENSE AGREEMENT WITH THE UNIVERSITY OF MINNESOTA - GT Biopharma, Inc.oxis_ex103.htm
EX-10.2 - LICENSE AGREEMENT WITH MULTICELL IMMUNOTHERAPEUTICS, INC. - GT Biopharma, Inc.oxis_ex102.htm
EX-10.1 - LICENSE AGREEMENT WITH ID4 PHARMA LLC - GT Biopharma, Inc.oxis_ex101.htm
 
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of GT Biopharma, Inc. (the “Company”), for the quarterly period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Tony Cataldo, Chief Executive Officer of the Company, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, do hereby certify, to my knowledge that:
 
(1)           The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 15 U.S.C. 78m(a) or 780(d)); and
 
(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: August 11, 2107
 
/s/ Tony Cataldo
 
 
 
Tony Cataldo
 
 
 
Chief Executive Officer, Chairman, and Director
 
 
 
 
 
 
A signed original of this written statement required by Section 906 has been provided to GT Biopharma, Inc. and will be retained by GT Biopharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
 

Stock widget

Investing forum

GT Biopharma, Inc. Reports